Af­ter No­vo Nordisk's ac­qui­si­tion of Cor­vidia, Ram Ai­yar takes the helm at Ko­r­ro Bio; Sil­ver­back gets a new CFO to go along with its IPO

→ Co-found­ed by Nes­san Berming­ham and bank­ing $91.5 mil­lion in Se­ries A fund­ing in Sep­tem­ber, RNA edit­ing start­up Ko­r­ro Bio has tapped Ram Ai­yar as their first CEO. Ai­yar, who be­gan as a re­search sci­en­tist in the im­munol­o­gy group at Janssen in the late 2000s, co-found­ed Cor­vidia Ther­a­peu­tics in 2016 and was al­so their CFO and CBO along the way. Back in June, Ai­yar helped steer the sale of Cor­vidia to No­vo Nordisk for $2.1 bil­lion, in­clud­ing $725 mil­lion up­front. With the deal, No­vo Nordisk in­sert­ed Cor­vidia’s IL-6 in­hibitor zil­tivekimab in­to their pipeline.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER